Chemed (CHE) Lowered to Hold at ValuEngine

Chemed (NYSE:CHE) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Friday.

Other equities analysts have also recently issued reports about the company. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $213.00 price objective for the company in a research note on Wednesday, August 23rd. Royal Bank Of Canada restated a “hold” rating and issued a $209.00 price objective on shares of Chemed in a research note on Friday, September 1st. KeyCorp restated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. Finally, Oppenheimer upped their price objective on Chemed from $220.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $236.00.

Chemed (CHE) traded up $1.59 during midday trading on Friday, hitting $247.53. The stock had a trading volume of 135,158 shares, compared to its average volume of 94,472. The company has a market cap of $3,920.00, a PE ratio of 29.80, a price-to-earnings-growth ratio of 5.12 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. Chemed has a 12-month low of $148.84 and a 12-month high of $248.31.

Chemed (NYSE:CHE) last released its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 EPS. analysts expect that Chemed will post 4.73 EPS for the current fiscal year.

In other news, insider David Patrick Williams sold 11,000 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total value of $2,654,080.00. Following the completion of the sale, the insider now directly owns 74,857 shares in the company, valued at approximately $18,061,496.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total value of $100,740.00. Following the completion of the sale, the director now owns 4,515 shares of the company’s stock, valued at $909,682.20. The disclosure for this sale can be found here. Insiders sold a total of 45,179 shares of company stock valued at $10,479,699 over the last 90 days. 4.90% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of CHE. Acrospire Investment Management LLC purchased a new stake in Chemed in the 2nd quarter worth $120,000. Pacad Investment Ltd. increased its stake in Chemed by 250.0% in the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after buying an additional 500 shares in the last quarter. IFP Advisors Inc increased its stake in Chemed by 1,504.5% in the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after buying an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Chemed by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after buying an additional 83 shares in the last quarter. Finally, MCF Advisors LLC purchased a new stake in Chemed in the 3rd quarter worth $152,000. Hedge funds and other institutional investors own 97.72% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Chemed (CHE) Lowered to Hold at ValuEngine” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/01/chemed-che-lowered-to-hold-at-valuengine.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit